98 related articles for article (PubMed ID: 10404072)
1. Antigen-specific cytotoxicity and cell number of adoptively transferred T cells are efficiently maintained in vivo by re-stimulation with an antigen/interleukin-2 fusion protein.
Kang BY; Lim YS; Chung SW; Kim EJ; Kim SH; Hwang SY; Kim TS
Int J Cancer; 1999 Aug; 82(4):569-73. PubMed ID: 10404072
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor.
Hornung RL; Longo DL; Bowersox OC; Kwak LW
J Natl Cancer Inst; 1995 Sep; 87(17):1289-96. PubMed ID: 7544833
[TBL] [Abstract][Full Text] [Related]
3. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
4. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production.
Kim TS; DeKruyff RH; Rupper R; Maecker HT; Levy S; Umetsu DT
J Immunol; 1997 May; 158(9):4137-44. PubMed ID: 9126973
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 expression and IFN-gamma secretion.
Kim TS; Chung SW; Kim SH; Kang SN; Kang BY
Int J Cancer; 2000 Aug; 87(3):427-33. PubMed ID: 10897050
[TBL] [Abstract][Full Text] [Related]
6. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
8. The effects of TCDD on the activation of ovalbumin (OVA)-specific DO11.10 transgenic CD4(+) T cells in adoptively transferred mice.
Shepherd DM; Dearstyne EA; Kerkvliet NI
Toxicol Sci; 2000 Aug; 56(2):340-50. PubMed ID: 10910992
[TBL] [Abstract][Full Text] [Related]
9. A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy.
Schülke S; Burggraf M; Waibler Z; Wangorsch A; Wolfheimer S; Kalinke U; Vieths S; Toda M; Scheurer S
J Allergy Clin Immunol; 2011 Dec; 128(6):1340-1348.e12. PubMed ID: 21872305
[TBL] [Abstract][Full Text] [Related]
10. Antigen-specific Il-4- and IL-10-secreting CD4+ lymphocytes increase in vivo susceptibility to Trypanosoma cruzi infection.
Barbosa de Oliveira LC; Curotto de Lafaille MA; Collet de Araujo Lima GM; de Almeida Abrahamsohn I
Cell Immunol; 1996 May; 170(1):41-53. PubMed ID: 8660798
[TBL] [Abstract][Full Text] [Related]
11. Covalent linkage of IL-12 and ovalbumin confines the effects of IL-12 to ovalbumin-specific immune responses.
Kim TS; Hwang SY; Yoo GS
Arch Pharm Res; 1997 Oct; 20(5):396-403. PubMed ID: 18982479
[TBL] [Abstract][Full Text] [Related]
12. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
[TBL] [Abstract][Full Text] [Related]
13. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
14. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
16. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
17. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
18. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
[TBL] [Abstract][Full Text] [Related]
19. Revealing the in vivo behavior of CD4+ T cells specific for an antigen expressed in Escherichia coli.
Chen ZM; Jenkins MK
J Immunol; 1998 Apr; 160(7):3462-70. PubMed ID: 9531307
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with an ovalbumin/interleukin-4 fusion DNA efficiently induces Th2 cell-mediated immune responses in an ovalbumin-specific manner.
Lim YS; Kang BY; Kim EJ; Kim SH; Hwang SY; Kim KM; Kim TS
Arch Pharm Res; 1998 Oct; 21(5):537-42. PubMed ID: 9875491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
